Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

By sjmartinez • April 9, 2024

Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Epub ahead of print. PMID: 38588819.

Tags: alanine aminotransferase, aspartate aminotransferase, bimekizumab, Dermatology, enzyme, Hepatic, Liver, liver fibrosis, plaque psoriasis, psoriasis, Publications, safety, transaminase

Response to Baroukhian et al., “Pemphigus following herpes simplex infection: A global comprehensive cohort study”

Curman P, Ngo BT, Hernandez G, Kridin K, Ludwig RJ, Kasperkiewicz M. Response to Baroukhian et al., "Pemphigus following herpes simplex infection: A global comprehensive[...]

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender VD, Castelo-Soccio L, Cotsarelis G, Craiglow BG, Desai[...]